Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Anticonvulsants Stories

2012-06-12 02:25:35

Fifth Annual Awards Competition Dedicated to Independent Pain Research KIRKLAND, QC, June 12, 2012 /CNW/ - Pfizer Canada is pleased to announce the recipients of the 2011 Neuropathic Pain Research Awards, an annual grant competition for independent research in the areas of basic biomedical, clinical and health service and systems sciences.(1) "For the past five years, the Neuropathic Pain Research Awards have supported Canadian medical innovation and research in neuropathic pain,"...

2012-06-11 23:01:04

The Consumer Justice Foundation, a for-profit corporation whose team of professional consumer advocates make it their mission to provide consumers with free online educational resources that deal with the potential risks of using certain prescription medications, has a Web site that can be found at the URL of http://www.depakotebirthinjury.com. The CJF hereby alerts the public that the State of Missouri has announced that it will be receiving $15 million from the $1.5 billion blanket...

2012-06-06 02:25:27

MENLO PARK, Calif., June 6, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced the issuance of a new patent expanding the patent estate around the company's Gralise® (gabapentin), Depomed's once-daily gabapentin product approved for the management of postherpetic neuralgia. The patent, United States Patent No. 8,192,756, expires in October 2022 and will be listed in the FDA "Orange Book" along with the six patents currently listed for Gralise. "We are particularly pleased...

2012-05-25 23:00:52

According to court documents, on January 18th 2012, an Illinois woman, Rhealyn Alexander, filed a lawsuit in the Illinois Southern District Court (case no. 3:2012cv00052) alleging that her daughter was born with severe birth defects caused by her use of Depakote. Depakote, manufactured by Abbott Laboratories, is a drug most commonly prescribed for psychiatric conditions like manic depressive disorder (bipolar disorder) and to prevent migraine headaches. In December 2010 and January 2011 more...

2012-05-17 23:04:25

The Consumer Justice Foundation, a for-profit corporation whose Web site URL can be found at http://www.depakotebirthinjury.com, is a team of professional consumer advocates who are driven to educate the public with regard to the potential dangers of using certain prescription medications. The CJF pursues this ideal by providing free online educational resources that detail these risks. The CJF further reports that Business Week has published an article stating that Abbott Laboratories, the...

2012-05-15 22:28:31

A novel mechanism for anxiety behaviors, including a previously unrecognized inhibitory brain signal, may inspire new strategies for treating psychiatric disorders, University of Chicago researchers report. By testing the controversial role of a gene called Glo1 in anxiety, scientists uncovered a new inhibitory factor in the brain: the metabolic by-product methylglyoxal. The system offers a tantalizing new target for drugs designed to treat conditions such as anxiety disorder, epilepsy,...

2012-05-07 10:24:25

WASHINGTON, May 7, 2012 /PRNewswire/ -- In what may be the largest payment ever enforced involving off-label misuse of a single drug, law firm Grant & Eisenhofer, working with the U.S. Justice Department and several state Attorneys General, has reached a $1.6 billion settlement with Abbott Laboratories over its illegal marketing of antiepileptic medication Depakote to children and geriatric patients. The settlement was reached between Abbott (NYSE: ABT) and the Justice Department, along...

2012-05-02 02:28:05

ATLANTA, May 2, 2012 /PRNewswire/ -- Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, announces the approval of an Abbreviated New Drug Application (ANDA) for Gabapentin Oral Solution, 250 mg/5 mL. The Food and Drug Administration (FDA) determined that Acella's ANDA is bioequivalent - therefore, therapeutically equivalent - to the reference listed drug, Neurontin®* Oral Solution, 250 mg/5 mL. "Acella looks forward to adding Gabapentin Oral Solution to our existing line...

2012-04-26 06:26:30

( ) ATLANTA, April 26, 2012 /PRNewswire/ -- UCB today announced interim results from the VITOBA(TM) (VImpaT® added to One Baseline AED) study, which showed that patients with less refractory partial-onset seizures treated with Vimpat® (lacosamide) C-V as add-on to monotherapy experienced seizure reduction. These data were presented today at the 64th annual meeting of the American Academy of Neurology (AAN) in New Orleans. VITOBA(TM) is a six-month prospective,...

2012-04-26 06:25:37

MAPLE GROVE, Minn., April 26, 2012 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (http://www.upsher-smith.com) today announced that three posters characterizing the pharmacokinetic (PK) profile of USL255, its once-daily, extended-release (ER) topiramate formulation, were presented at the 64th Annual American Academy of Neurology (AAN) Meeting. One of the posters showed equivalent exposure between USL255 and equal doses of immediate-release (IR) topiramate at steady state, a second poster...